Humana (HUM) Stock Forecast & Price Target

Compare

17 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HUM Analyst Ratings

Hold

5 Buy

12 Hold

2 Sell

Based on 19 analysts giving stock ratings to

Humana

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HUM Stock 12 Month Forecast

Average Price Target

€187.37

▲(26.68% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Humana in the last 3 months. The average price target is €187.37 with a high forecast of €299.79 and a low forecast of €127.23. The average price target represents a 26.68% change from the last price of €147.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"126":"€126","213":"€213","300":"€300","169.5":"€169.5","256.5":"€256.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":299.78579352,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€299.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":187.36612095,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€187.37</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":127.23466818,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€127.23</span>\n  </div></div>","useHTML":true}}],"tickPositions":[126,169.5,213,256.5,300],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,159.2,170.01429180923077,180.82858361846152,191.6428754276923,202.45716723692308,213.27145904615384,224.08575085538462,234.9000426646154,245.71433447384618,256.52862628307696,267.34291809230774,278.15720990153847,288.97150171076925,{"y":299.78579352,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,159.2,161.36662468846154,163.53324937692307,165.69987406538462,167.86649875384614,170.0331234423077,172.19974813076922,174.36637281923078,176.5329975076923,178.69962219615385,180.86624688461538,183.03287157307693,185.19949626153846,{"y":187.36612095,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,159.2,156.74112832153844,154.28225664307692,151.82338496461537,149.36451328615385,146.9056416076923,144.44676992923075,141.98789825076923,139.52902657230769,137.07015489384617,134.61128321538462,132.15241153692307,129.69353985846155,{"y":127.23466818,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":247.802,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":241.364,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":225.181,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":203.04,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.789,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":216.253,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":256.614,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":210.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":240.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":208.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":218.1,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.05,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.2,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€299.79

Average Price Target€187.37

Lowest Price Target€127.23

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Windley

Jefferies

€203.77

Buy

37.78%

Upside

Reiterated

02/27/26

Jefferies Keeps Their Buy Rating on Humana (HUM)

Stephen Baxter

Wells Fargo

€178.62

Hold

20.77%

Upside

Reiterated

02/25/26

Wells Fargo Sticks to Its Hold Rating for Humana (HUM)

Andrew Mok CFA

Barclays

€212.44→€152.61

Hold

3.19%

Upside

Reiterated

02/25/26

Barclays Remains a Hold on Humana (HUM)

George Hill

Deutsche Bank

―

Hold

―

Reiterated

02/20/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (NYSE: HUM), Summit Therapeutics (NASDAQ: SMMT) and Intuitive Surgical (NASDAQ: ISRG)

David S Macdonald

Truist Financial

€247.13→€173.42

Hold

17.26%

Upside

Reiterated

02/17/26

Truist Financial Reaffirms Their Hold Rating on Humana (HUM)

A.J. Rice

UBS

€169.09

Hold

14.32%

Upside

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: Aethlon Medical (NASDAQ: AEMD), Humana (NYSE: HUM) and Palvella Therapeutics (NASDAQ: PVLA)

Scott Fidel

Goldman Sachs

€137

Sell

-7.37%

Downside

Reiterated

02/17/26

Goldman Sachs Keeps Their Sell Rating on Humana (HUM)

Elizabeth Anderson CFA

Evercore ISI

€156.08

Hold

5.53%

Upside

Reiterated

02/17/26

Analysts Are Neutral on Top Healthcare Stocks: 10x Genomics (TXG), Moderna (MRNA)

Lisa Gill

J.P. Morgan

€237.59→€156.08

Hold

5.53%

Upside

Reiterated

02/13/26

Analysts Offer Insights on Healthcare Companies: Zoetis (NYSE: ZTS), Humana (NYSE: HUM) and 10x Genomics (NASDAQ: TXG)

Erin Wright

Morgan Stanley

€150.88→€126.6

Sell

-14.40%

Downside

Reiterated

02/12/26

Humana price target lowered to $146 from $174 at Morgan StanleyHumana price target lowered to $146 from $174 at Morgan Stanley

Michael Wiederhorn

Oppenheimer

€216.78

Buy

46.57%

Upside

Reiterated

02/12/26

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND) and Humana (NYSE: HUM)

Ben Hendrix

RBC Capital

€279.21→€163.88

Hold

10.81%

Upside

Downgraded

02/12/26

Humana downgraded to Sector Perform from Outperform at RBC CapitalHumana downgraded to Sector Perform from Outperform at RBC Capital

Matthew Gillmor CFA

KeyBanc

―

Hold

―

Reiterated

02/12/26

Analysts Offer Insights on Healthcare Companies: Humana (NYSE: HUM), Inspire Medical Systems (NYSE: INSP) and Avantor (NYSE: AVTR)

Ryan Langston

TD Cowen

€150.01

Hold

1.43%

Upside

Reiterated

02/12/26

Balanced Risk-Reward Amid Growth Ambitions and Margin Rebuild Supports Humana Hold Rating

Kevin Fischbeck

Bank of America Securities

€225.45

Hold

52.43%

Upside

Reiterated

02/11/26

Analysts Offer Insights on Healthcare Companies: Qiagen (NYSE: QGEN) and Humana (NYSE: HUM)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Windley

Jefferies

€203.77

Buy

37.78%

Upside

Reiterated

02/27/26

Jefferies Keeps Their Buy Rating on Humana (HUM)

Stephen Baxter

Wells Fargo

€178.62

Hold

20.77%

Upside

Reiterated

02/25/26

Wells Fargo Sticks to Its Hold Rating for Humana (HUM)

Andrew Mok CFA

Barclays

€212.44→€152.61

Hold

3.19%

Upside

Reiterated

02/25/26

Barclays Remains a Hold on Humana (HUM)

George Hill

Deutsche Bank

―

Hold

―

Reiterated

02/20/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (NYSE: HUM), Summit Therapeutics (NASDAQ: SMMT) and Intuitive Surgical (NASDAQ: ISRG)

David S Macdonald

Truist Financial

€247.13→€173.42

Hold

17.26%

Upside

Reiterated

02/17/26

Truist Financial Reaffirms Their Hold Rating on Humana (HUM)

A.J. Rice

UBS

€169.09

Hold

14.32%

Upside

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: Aethlon Medical (NASDAQ: AEMD), Humana (NYSE: HUM) and Palvella Therapeutics (NASDAQ: PVLA)

Scott Fidel

Goldman Sachs

€137

Sell

-7.37%

Downside

Reiterated

02/17/26

Goldman Sachs Keeps Their Sell Rating on Humana (HUM)

Elizabeth Anderson CFA

Evercore ISI

€156.08

Hold

5.53%

Upside

Reiterated

02/17/26

Analysts Are Neutral on Top Healthcare Stocks: 10x Genomics (TXG), Moderna (MRNA)

Lisa Gill

J.P. Morgan

€237.59→€156.08

Hold

5.53%

Upside

Reiterated

02/13/26

Analysts Offer Insights on Healthcare Companies: Zoetis (NYSE: ZTS), Humana (NYSE: HUM) and 10x Genomics (NASDAQ: TXG)

Erin Wright

Morgan Stanley

€150.88→€126.6

Sell

-14.40%

Downside

Reiterated

02/12/26

Humana price target lowered to $146 from $174 at Morgan StanleyHumana price target lowered to $146 from $174 at Morgan Stanley

Michael Wiederhorn

Oppenheimer

€216.78

Buy

46.57%

Upside

Reiterated

02/12/26

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND) and Humana (NYSE: HUM)

Ben Hendrix

RBC Capital

€279.21→€163.88

Hold

10.81%

Upside

Downgraded

02/12/26

Humana downgraded to Sector Perform from Outperform at RBC CapitalHumana downgraded to Sector Perform from Outperform at RBC Capital

Matthew Gillmor CFA

KeyBanc

―

Hold

―

Reiterated

02/12/26

Analysts Offer Insights on Healthcare Companies: Humana (NYSE: HUM), Inspire Medical Systems (NYSE: INSP) and Avantor (NYSE: AVTR)

Ryan Langston

TD Cowen

€150.01

Hold

1.43%

Upside

Reiterated

02/12/26

Balanced Risk-Reward Amid Growth Ambitions and Margin Rebuild Supports Humana Hold Rating

Kevin Fischbeck

Bank of America Securities

€225.45

Hold

52.43%

Upside

Reiterated

02/11/26

Analysts Offer Insights on Healthcare Companies: Qiagen (NYSE: QGEN) and Humana (NYSE: HUM)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Humana

3 Months

xxx

Success Rate

26/41 ratings generated profit

Average Return

+1.33%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.41% of your transactions generating a profit, with an average return of +1.33% per trade.

1 Year

Scott FidelGoldman Sachs

Success Rate

12/22 ratings generated profit

Average Return

+2.36%

Copying Scott Fidel's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +2.36% per trade.

2 Years

xxx

Success Rate

14/22 ratings generated profit

Average Return

+1.71%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 63.64% of your transactions generating a profit, with an average return of +1.71% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HUM Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HUM has received 11 Buy Ratings, 24 Hold Ratings, and 3 Sell Ratings. HUM average Analyst price target in the past 3 months is 187.37.

Each month's total comprises the sum of three months' worth of ratings.

HUM Financial Forecast

HUM Earnings Forecast

Next quarter’s earnings estimate for HUM is €8.72 with a range of €5.43 to €11.31. The previous quarter’s EPS was -€3.45. HUM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year HUM has Performed in-line its overall industry.

HUM Sales Forecast

Next quarter’s sales forecast for HUM is €33.86B with a range of €30.11B to €36.25B. The previous quarter’s sales results were €28.34B. HUM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year HUM has Performed in-line its overall industry.

HUM Stock Forecast FAQ

What is DE:HUM’s average 12-month price target, according to analysts?

Based on analyst ratings, Humana’s 12-month average price target is 187.37.

What is DE:HUM’s upside potential, based on the analysts’ average price target?

Humana has 26.68% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Humana a Buy, Sell or Hold?

Humana has a consensus rating of Hold, which is based on 5 buy ratings, 12 hold ratings and 2 sell ratings.

What is Humana’s share price target?

The average share price target for Humana is 187.37. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €299.79 ,and the lowest forecast is €127.23. The average share price target represents 26.68% Increase from the current price of €147.9.

What do analysts say about Humana?

Humana’s analyst rating consensus is a Hold. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of Humana?

To buy shares of DE:HUM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Humana (HUM) Stock Forecast & Price Target

HUM Analyst Ratings

HUM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Humana

HUM Analyst Recommendation Trends

HUM Financial Forecast

HUM Earnings Forecast

HUM Sales Forecast

HUM Stock Forecast FAQ

Detailed List of Analyst Forecasts